Secures $150K Bridge Loan, Plans $1.4M Convertible Note Financing with 35% Discount for Business Combination Expenses

summarizeSummary

Drugs Made In America Acquisition II Corp. secured a $150,000 convertible bridge loan as part of a planned $1.4 million financing, with conversion at a 35% discount, to cover expenses for its business combination.

check_boxKey Events

• Bridge Loan Secured

  The company issued a $150,000 unsecured convertible bridge note to Alpha Multi Family Office on March 11, 2026.

• Planned Larger Financing

  This bridge loan is the first payment towards a contemplated $1.4 million convertible notes financing, outlined in a Letter of Intent dated March 5, 2026, and an Addendum dated March 9, 2026.

• Highly Dilutive Conversion Terms

  The notes are convertible at the investor's option after a business combination, at a significant 35% discount to the market price of the combined entity's shares.

• Use of Proceeds

  Proceeds from the bridge loan are intended for accounting, audit, and other expenses related to the company's business combination, crucial for maintaining operations and listing.

auto_awesomeAnalysis

Drugs Made In America Acquisition II Corp. has secured a $150,000 unsecured convertible bridge note, which is the initial tranche of a contemplated $1.4 million convertible notes financing. This financing is critical for the company to cover accounting, audit, and regulatory expenses necessary to maintain its listing and pursue a business combination. The terms are highly dilutive, allowing conversion at a 35% discount to the market price of the combined entity's shares, indicating the company's urgent need for capital. This development follows recent governance issues, including the removal of the CEO and Executive Chair due to the sponsor's failure to repay a loan, making this financing a crucial step for the company's continued operation and de-SPAC efforts.